SK bioscience's Innovative RSV Preventive Antibody Candidate Advances to Global Phase 1b Clinical Trial#South_Korea#Incheon#SK_bioscience#RSV_Prevention#RSM01
SK bioscience's Innovative RSV Preventive Antibody Candidate Advances to Global Phase 1b Clinical Trial
SK bioscience has submitted a Clinical Trial Application for its RSV preventive antibody candidate, RSM01, to commence a Phase 1b study targeting infants. This initiative aims to bolster infectious disease prevention efforts globally.
third-news.com
August 14, 2026 at 12:10 PM
SK bioscience's Innovative RSV Preventive Antibody Candidate Advances to Global Phase 1b Clinical Trial#South_Korea#Incheon#SK_bioscience#RSV_Prevention#RSM01
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions#South_Korea#Incheon#SK_bioscience#Vaccine_Development#ROTOR
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions
SK bioscience launches an AI-driven project to streamline clinical development decisions, aiming to enhance global vaccine access, especially in low-income nations.
third-news.com
July 2, 2026 at 12:04 PM
SK bioscience Unveils AI Initiative to Enhance Vaccine Development Decisions#South_Korea#Incheon#SK_bioscience#Vaccine_Development#ROTOR
SK bioscience Partners with Global Institutions to Boost Rotavirus Vaccine Development#South_Korea#CDC#Incheon#SK_bioscience#Rotavirus_Vaccine
SK bioscience Partners with Global Institutions to Boost Rotavirus Vaccine Development
SK bioscience has joined forces with global partners to enhance its rotavirus vaccine development. The company aims at improving global public health with innovative solutions.
third-news.com
June 9, 2026 at 12:20 PM
SK bioscience Partners with Global Institutions to Boost Rotavirus Vaccine Development#South_Korea#CDC#Incheon#SK_bioscience#Rotavirus_Vaccine
SK Bioscience's Groundbreaking UNICEF Contract Enhances Global Vaccine Access#South_Korea#Incheon#SK_bioscience#Flu_Vaccine#UNICEF_Contract
SK Bioscience's Groundbreaking UNICEF Contract Enhances Global Vaccine Access
SK Bioscience has secured a pivotal contract with UNICEF to supply flu vaccines, enhancing global immunization efforts and improving vaccine access in underserved regions.
third-news.com
June 2, 2026 at 12:43 PM
SK Bioscience's Groundbreaking UNICEF Contract Enhances Global Vaccine Access#South_Korea#Incheon#SK_bioscience#Flu_Vaccine#UNICEF_Contract
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea#South_Korea#Incheon#SK_bioscience#Vaccine_Development#Korea_Growth_Fund
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea
SK bioscience has received board approval for a KRW 300 billion funding from the Korea Growth Fund, enhancing its ambitious vaccine development projects aimed at global health.
third-news.com
May 29, 2026 at 12:07 PM
SK biocience Secures Major Funding to Boost Vaccine Development in South Korea#South_Korea#Incheon#SK_bioscience#Vaccine_Development#Korea_Growth_Fund
SK bioscience Collaborates with VECOL for Vaccine Manufacturing in Colombia#Colombia#Incheon#SK_bioscience#Vaccine_Production#VECOL
SK bioscience Collaborates with VECOL for Vaccine Manufacturing in Colombia
SK bioscience has partnered with VECOL to enhance local vaccine manufacturing in Colombia, marking a significant step towards improved healthcare in Latin America.
third-news.com
May 26, 2026 at 12:15 PM
SK bioscience Collaborates with VECOL for Vaccine Manufacturing in Colombia#Colombia#Incheon#SK_bioscience#Vaccine_Production#VECOL
SK bioscience Secures Major Funding to Propel RSV Antibody Development Globally#South_Korea#Incheon#SK_bioscience#RSV_antibody#RIGHT_Foundation
SK bioscience Secures Major Funding to Propel RSV Antibody Development Globally
SK bioscience has secured funding from the RIGHT Foundation to advance the development of an RSV preventive monoclonal antibody. This pivotal support will enhance clinical trials for transforming global health.
third-news.com
March 18, 2026 at 12:33 PM
SK bioscience Secures Major Funding to Propel RSV Antibody Development Globally#South_Korea#Incheon#SK_bioscience#RSV_antibody#RIGHT_Foundation
Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe#South_Korea#Incheon#SK_bioscience#IDT_Biologika#Vaxxas
Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe
SK bioscience, IDT Biologika, and Vaxxas join forces to develop next-generation influenza vaccines, aiming to enhance public health resilience and accessibility.
third-news.com
February 27, 2026 at 4:31 AM
Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe#South_Korea#Incheon#SK_bioscience#IDT_Biologika#Vaxxas
SK bioscience Advances RSV Prevention with Novel Monoclonal Antibody Through Gates MRI License#South_Korea#RSV#Incheon#SK_bioscience#Gates_Medical_Research
SK bioscience Advances RSV Prevention with Novel Monoclonal Antibody Through Gates MRI License
SK bioscience is set to develop a new monoclonal antibody for RSV prevention, showcasing a commitment to equitable global health through a recent partnership with Gates MRI.
third-news.com
February 3, 2026 at 1:20 PM
SK bioscience Advances RSV Prevention with Novel Monoclonal Antibody Through Gates MRI License#South_Korea#RSV#Incheon#SK_bioscience#Gates_Medical_Research
SK bioscience Launches Phase 1/2 Trial for Universal Sarbecovirus Vaccine in Australia#Australia#Incheon#SK_bioscience#GBP511#SKYCovione
SK bioscience Launches Phase 1/2 Trial for Universal Sarbecovirus Vaccine in Australia
SK bioscience has commenced a global Phase 1/2 trial in Australia for GBP511, a universal vaccine targeting the sarbecovirus family, aiming for pandemic preparedness.
third-news.com
January 29, 2026 at 1:30 PM
SK bioscience Launches Phase 1/2 Trial for Universal Sarbecovirus Vaccine in Australia#Australia#Incheon#SK_bioscience#GBP511#SKYCovione
New Collaboration to Accelerate Zaire Ebola Vaccine Development with CEPI Support#South_Korea#Incheon#SK_bioscience#MSD#Zaire_Ebolavirus
New Collaboration to Accelerate Zaire Ebola Vaccine Development with CEPI Support
SK bioscience collaborates with MSD and Hilleman Labs, backed by CEPI funding, to enhance the Zaire ebolavirus vaccine accessibility and stability.
third-news.com
January 22, 2026 at 1:17 PM
New Collaboration to Accelerate Zaire Ebola Vaccine Development with CEPI Support#South_Korea#Incheon#SK_bioscience#MSD#Zaire_Ebolavirus
IDT Biologika Accelerates Global CDMO Growth in Vaccines and Biopharmaceuticals#Germany#Frankfurt#CDMO#SK_bioscience#IDT_Biologika
IDT Biologika Accelerates Global CDMO Growth in Vaccines and Biopharmaceuticals
IDT Biologika is enhancing its CDMO capabilities globally, focusing on vaccine production and biopharmaceuticals. Key global events highlighted its strengths in manufacturing.
third-news.com
November 5, 2025 at 1:22 PM
IDT Biologika Accelerates Global CDMO Growth in Vaccines and Biopharmaceuticals#Germany#Frankfurt#CDMO#SK_bioscience#IDT_Biologika
SK bioscience Advances Towards First-in-Human Trial for Universal Coronavirus Vaccine in Australia#Australia#Seongnam#COVID-19_vaccine#SK_bioscience#Universal_Vaccine
SK bioscience Advances Towards First-in-Human Trial for Universal Coronavirus Vaccine in Australia
SK bioscience has filed for a Phase 1/2 trial of its universal coronavirus vaccine in Australia, aiming to combat COVID-19 and related variants with results expected by 2028.
third-news.com
October 15, 2025 at 12:19 PM
SK bioscience Advances Towards First-in-Human Trial for Universal Coronavirus Vaccine in Australia#Australia#Seongnam#COVID-19_vaccine#SK_bioscience#Universal_Vaccine
SK bioscience Takes Major Step Forward with IND Submission for 2-Dose Varicella Vaccine Phase 3 Trial#South_Korea#Seongnam#SK_bioscience#Varicella_Vaccine#SKYVaricella
SK bioscience Takes Major Step Forward with IND Submission for 2-Dose Varicella Vaccine Phase 3 Trial
SK bioscience has submitted an IND to initiate a Phase 3 trial for its 2-dose varicella vaccine, aligning with global vaccination standards and addressing rising market demand.
third-news.com
September 2, 2025 at 11:17 AM
SK bioscience Takes Major Step Forward with IND Submission for 2-Dose Varicella Vaccine Phase 3 Trial#South_Korea#Seongnam#SK_bioscience#Varicella_Vaccine#SKYVaricella
SK bioscience and Gates Foundation Strengthen Global Health Initiatives Together#South_Korea#Seoul#Gates_Foundation#Global_Health#SK_bioscience
SK bioscience and Gates Foundation Strengthen Global Health Initiatives Together
SK bioscience recently met with the Gates Foundation to discuss advancements in global health and the development of next-generation preventive medicines. Discover more about their collaborative efforts.
third-news.com
August 21, 2025 at 12:15 PM
SK bioscience and Gates Foundation Strengthen Global Health Initiatives Together#South_Korea#Seoul#Gates_Foundation#Global_Health#SK_bioscience
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#adjuvant_technology
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission
SK bioscience has submitted an IND application for a Phase 1/2 clinical trial of a new adjuvanted influenza vaccine, aiming to enhance protective efficacy for vulnerable populations.
third-news.com
July 17, 2025 at 11:08 AM
SK bioscience Takes a Big Step with New Influenza Vaccine Candidate IND Submission#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#adjuvant_technology
SK Bioscience Achieves Legal Victory Against Pfizer in Pneumococcal Vaccine Patent Dispute#South_Korea#Seongnam#SK_bioscience#Pfizer#PCV13
SK Bioscience Achieves Legal Victory Against Pfizer in Pneumococcal Vaccine Patent Dispute
SK Bioscience has won a crucial patent lawsuit against Pfizer regarding its pneumococcal vaccine, paving the way for future vaccine development and exportation.
third-news.com
May 21, 2025 at 12:27 PM
SK Bioscience Achieves Legal Victory Against Pfizer in Pneumococcal Vaccine Patent Dispute#South_Korea#Seongnam#SK_bioscience#Pfizer#PCV13
IDT Biologika Amplifies Global Role via Strategic CDMO Alliances#South_Korea#Seongnam#CDMO#SK_bioscience#IDT_Biologika
IDT Biologika Amplifies Global Role via Strategic CDMO Alliances
IDT Biologika is enhancing its global footprint through strategic partnerships and participation in major international bio events.
third-news.com
May 20, 2025 at 12:28 PM
IDT Biologika Amplifies Global Role via Strategic CDMO Alliances#South_Korea#Seongnam#CDMO#SK_bioscience#IDT_Biologika
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns#South_Korea#Seongnam#Avian_Influenza#SK_bioscience#Vaccine_Development
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns
SK bioscience collaborates with Korea Disease Control and Prevention Agency to create a rapid-response avian influenza vaccine to enhance global health security.
third-news.com
May 6, 2025 at 12:37 PM
SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns#South_Korea#Seongnam#Avian_Influenza#SK_bioscience#Vaccine_Development
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#SKYCellflu
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets
SK bioscience has commenced the export of its SKYCellflu influenza vaccine to Southern Hemisphere markets, enhancing global vaccine access and production stability.
third-news.com
March 12, 2025 at 12:15 PM
SK bioscience Accelerates Global Outreach by Exporting Influenza Vaccines to Southern Hemisphere Markets#South_Korea#Seongnam#Influenza_vaccine#SK_bioscience#SKYCellflu
SK bioscience Launches Global Clinical Trials for mRNA Vaccine Against Japanese Encephalitis#South_Korea#Seongnam#SK_bioscience#mRNA_Vaccine#Japanese_Encephalitis
SK bioscience Launches Global Clinical Trials for mRNA Vaccine Against Japanese Encephalitis
SK bioscience has initiated Phase 1/2 clinical trials of its mRNA vaccine for Japanese encephalitis, aiming for rapid pandemic response and global accessibility.
third-news.com
February 25, 2025 at 1:20 PM
SK bioscience Launches Global Clinical Trials for mRNA Vaccine Against Japanese Encephalitis#South_Korea#Seongnam#SK_bioscience#mRNA_Vaccine#Japanese_Encephalitis
SK bioscience Launches mRNA Vaccine Trials for Japanese Encephalitis, Aiming for Global Impact#South_Korea#Seongnam#SK_bioscience#mRNA_Vaccine#Japanese_Encephalitis
SK bioscience Launches mRNA Vaccine Trials for Japanese Encephalitis, Aiming for Global Impact
SK bioscience has received approval for clinical trials of its mRNA vaccine candidate against Japanese encephalitis, aiming for swift global response.
third-news.com
December 12, 2024 at 1:25 PM
SK bioscience Launches mRNA Vaccine Trials for Japanese Encephalitis, Aiming for Global Impact#South_Korea#Seongnam#SK_bioscience#mRNA_Vaccine#Japanese_Encephalitis